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licenses/by-nc-sa/4.0/).AIM: To assess the safety of gadobutrol administration in elderly patients (65 years) by
comparing the incidence of adverse drug reactions (ADRs) following gadobutrol-enhanced
magnetic resonance imaging (MRI) procedures in elderly patients with that in adults aged
18e64 years.
MATERIALS AND METHODS: Safety data on gadobutrol administration from clinical trials,
post-marketing surveillance (PMS) studies, and pharmacovigilance reports were collected in
three databases. In each dataset, absolute and relative frequencies of ADRs between age groups
were analysed, along with odds ratios and 95% conﬁdence intervals. Logistic regression was
used to identify signiﬁcant inﬂuencing factors on ADRs in the PMS and pharmacovigilance
data.
RESULTS: Rates of reported ADRs were lower in elderly patients versus adults aged <65
years due to a reduced incidence of non-serious ADRs; this was statistically signiﬁcant for the
clinical trials and pharmacovigilance populations, with a trend in the PMS database. Serious
ADRs occurred infrequently in the clinical trials and PMS populations (too low for statistical
comparison), and pharmacovigilance data demonstrated a low incidence (<0.005%) in both
age groups.
CONCLUSIONS: This evaluation involving three large databases demonstrated no greater
incidence of ADRs following gadobutrol-enhanced MRI in elderly patients (65 years)
compared with younger adults, with gadobutrol having a favourable safety proﬁle in both age
groups.
 2015 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access
article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/4.0/).lobal Medical & Clinical Affairs Radiology, Radiology & Interventional, Bayer HealthCare Medical Care,
49 30 468 194306; fax: þ49 30 468 994306.
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Gadolinium-based contrast agents (GBCAs) are used in
magnetic resonance imaging (MRI) examinations to in-
crease diagnostic conﬁdence for the diagnosis of various
conditions throughout the body. Gadobutrol, a macrocyclic
GBCA with a 1 M concentration, has a proven favourable
safety and efﬁcacy proﬁle and is approved for a wide range
of MRI indications in all body regions in adults and child-
rene.1e4 Gadobutrol is a second-generation (higher con-
centration and higher relaxivity compared with earlier
agents), non-ionic GBCA, with favourable physicochemical
properties that enable the formulation of a 1 M solution.2
Gadobutrol’s 1 M concentration allows smaller injection
volumes to be used versus 0.5 M agents.2
Worldwide, there is a trend toward an aging population,
due in part to increasing longevity, which may be related to
improvements in primary disease prevention and health-
care provision.5 Aging is frequently accompanied by chronic
disease, comorbidity, frailty, and disability,5 meaning that
an aging population is predicted to undergo increasing
numbers of diagnostic procedures, including MRI exami-
nations. Due to this trend for greater numbers of comor-
bidities, elderly adults (aged >65 years) also tend to take a
higher number of different drugs (polypharmacy) than
younger adults.5 Consideration of the health status of
elderly patient is important with regard to administration
of GBCAs, as these agents are excreted via the renal system
(glomerular ﬁltration) and elderly patients may have a
decreased glomerular ﬁltration rate.6 An adverse reaction to
a GBCA in a frail elderly patient might be expected to have a
more severe outcome compared with a similar reaction in a
healthier younger patient. Additionally, elderly patients
with comorbidities may have an increased likelihood of
adverse outcomes following medical procedures, due to the
risks associated with polypharmacy and age-related
changes in pharmacokinetic parameters and organ
impairments.5
Adverse drug reactions (ADRs) are commonly used as a
measure of the safety of pharmaceutical compounds,
including contrast media. Results from randomised
controlled trials provide reliable, unbiased evidence for the
safety of contrast agents, while post-marketing surveillance
(PMS) studies and pharmacovigilance reports add valuable
data on “real-life” use of contrast agents in a large and
varied population of patients, including the occurrence and
frequency of rare ADRs. Previous analyses have reported on
the safety of gadobutrol in a number of different patient
populations,1,3,7 but none have focused on the elderly
population. The aim of this analysis was, therefore, to
evaluate the incidence of ADRs following gadobutrol
administration in elderly patients (aged 65 years)
compared with that in adults aged<65 years (18e64 years),
using three databases containing safety data from clinicale Gadobutrol is approved for children and adolescents from 2e17 years of age i
Canada, China, Korea, Australia, Philippines, and Mexico, among others. In the U
imaging of the central nervous system and assessment of malignant breast disetrials, PMS studies, and pharmacovigilance reports,
respectively. To the authors’ knowledge, this is the ﬁrst
dedicated publication on the safety of an extracellular
contrast agent in the elderly population.
Materials and methods
All available safety data on gadobutrol administration
within clinical trials, and in clinical practice following
marketing approval, were collected. Statistical analyses
were performed on the collective data sets (three separate
databases) to compare the incidence of ADRs (non-serious
ADRs, and serious ADRs where numbers of events were
high enough for meaningful comparison) between subjects
of two age groups: elderly patients aged 65 years and
adults aged 18e64 years. Categorical data were recorded as
absolute and relative frequencies and two-sided p-values
<0.05 were regarded as statistically signiﬁcant. Statistical
analysis was performed using SAS version 9.2 (SAS Institute,
Cary, NC, USA) and NCSS 2007 (NCSS, Kaysville, UT, USA).
For the calculation of the odds ratios (ORs) for the com-
parison of age groups, the value 0.5 was added to each cell
of the 22 table to avoid zero counts in any cell (95% con-
ﬁdence intervals [CIs] were based on non-central hyper-
geometric distribution and the exact test, allowing at least
one conﬁdence limit to be estimated for assessment of
whether the OR was different from 1).
ADRs were deﬁned as any adverse reaction following a
gadobutrol-enhancedMRI procedure, which may be at least
possibly related to gadobutrol administration. A serious
ADR was deﬁned as any ADR resulting in death, disability, a
life-threatening condition, hospitalisation, or an extension
of hospitalisation.
Clinical trials data
The clinical study database included all Bayer
HealthCare-sponsored gadobutrol studies conducted be-
tween 1992 and 2013, involving combined data from par-
ticipants in 38 prospective Phase 2 to 4 trials. All trials were
conducted in accordance with the Declaration of Helsinki
and approved by the relevant local institutional review
board. ADR reporting and evaluation was standardised
across all studies, and all ADRs were categorised byMedical
Dictionary for Regulatory Activities system organ class (SOC)
and rated for severity. ADRs were recorded during an
observation period of 24 to 72 hours following gadobutrol
administration. The data were analysed descriptively along
with pure ORs and exact 95% CIs. No adjustment for co-
factors was included.
PMS data
Reported ADRs from six prospective PMS studies, con-
ducted at 300 centres in 11 countries (Austria, Canada,n different markets, including countries of the European Union, Switzerland,
SA, gadobutrol is approved for all age groups, including term neonates, for
ase.
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Slovenia, Spain, Sweden, and Turkey) were included.7 All
studies were approved by the relevant institutional review
board, had similar methodologies with respect to ADR
reporting, and all ADRs were assessed similarly to those
from the clinical trials. The inﬂuence of the cofactors
gender, dose per kilogram of bodyweight (b.w.), and pres-
ence of any allergies were considered. “Study” was included
as a random factor to account for differences between the
studies (e.g., study size and proportions of each age group).
Logistic regression was used to identify signiﬁcant inﬂu-
encing factors by backward selection. The ﬁnal model
contained only the signiﬁcant factors, using all patients
with complete data on these factors. Odds ratios were
calculated for signiﬁcant factors along with 95% Wald con-
ﬁdence intervals. Analyses were conducted for total ADR
incidence rates only; the number of serious ADRs was
insufﬁcient for statistical analyses.
Pharmacovigilance reporting data
All ADRs reported to the Bayer pharmacovigilance
department following gadobutrol administration were
included, up to the cut-off date of 26 February 2013.
Pharmacovigilance reports commonly included basic pa-
tient information (age, sex, weight, height, or a local
identiﬁcation number) along with a brief description of the
ADR. All ADRs were categorised similarly to those from the
clinical trials database. Due to the nature of pharmacovi-
gilance data reporting, while the number of patients for
whom an ADR was reported is known, the total number of
people who received gadobutrol as part of a contrast-
enhanced MRI procedure during the reporting period
(1999e2013) is unknown. To estimate the overall incidence
rate of ADRs in all patients who received gadobutrol, uti-
lisation data for the whole reporting period would be
required; however, utilisation data are only available for
the period of 2007 to 2011, allowing estimation of ADR
rates for this period. Utilisation was estimated based on
litre volume sold (according to Bayer internal reporting
and assuming a 10 ml average dose) and data on clinical
administrations to patients collected directly from radi-
ology centres in Europe, the USA, and Asia (annual Imaging
Market Guides 2007 to 2011 from Arlington Medical Re-
sources [AMR], Exton, PA, USA), which included patient
demographic information (age, sex) and reasons for per-
forming contrast-enhanced MRI.8 Using these utilisation
data to approximate the total number of patients to whom
gadobutrol was administered, the odds of experiencing at
least one ADR or serious ADR in each age group were
estimated.
Logistic regression was used for binary data and multi-
nomial regression was used for categorical data. The co-
factors of gender and global region were accounted for, as
well as the interactions of these cofactors with age, using
likelihood ratio statistics for Type 3 analyses. All ADRs by
SOC, and the reported rates of serious ADRs and deaths,
were compared between the age groups. For serious ADRs
and deaths, ORs were provided with Wald 95% CIs.Results
Clinical trials data
The clinical trials database included 5608 patients for
whom age data were available; 3911 adults <65 years (aged
18e64 years) and 1697 elderly (aged 65 years). The age-
categorised populations were similar with regard to the
dose of gadobutrol received (mean 0.10 mmol/kg b.w. for
each), but there were some differences in terms of gender
and global region representation (Table 1).
Overall, 150 adults aged <65 years (3.8%) and 46
elderly patients (2.7%) reported an ADR (Table 1). The OR
for a comparison between the age groups favoured the
elderly population, with signiﬁcantly fewer reported ADRs
in these patients (p ¼ 0.0392). Fewer ADRs in many in-
dividual SOC categories were also reported in the elderly
population as compared with adults aged <65 years,
although some individual ADRs were reported more often
in elderly patients; for example, feeling hot (Table 1). No
serious ADRs or deaths were reported in either
population.
PMS data
The PMS database included 14,064 patients for whom
age data were available; 9664 adults aged <65 years and
4400 elderly. Differences between the age groups were
noted in terms of gender (a higher proportion of adults aged
<65 years were female) and dosing (higher doses
[0.20 mmol/kg b.w.] were reported for a greater propor-
tion of the elderly population). Elderly patients exhibited a
lower incidence of history of allergy than adults aged <65
years (Table 2), but this difference did not reach statistical
signiﬁcance.
Overall, 64 non-serious ADRs were reported; 13 (0.3%)
in the elderly and 51 (0.5%) in adults <65 years. Although
the ADR incidence was numerically lower in the elderly
population, the comparison with the adult population did
not reach statistical signiﬁcance (OR: 0.56; 95% CI:
0.30e1.03; p ¼ 0.0614). In modelling analyses, the co-
factors gender and dose were not found to be signiﬁcant
and were deselected in the logistic regression analysis
using backward selection of signiﬁcant factors. A history of
allergy, however, had an effect on the ADR rate and further
logistic regression analysis was performed to analyse the
effect by incorporating the cofactor “history of allergy” into
the logistic model when estimating the OR for the com-
parison between age groups. The OR without adjustment
was 0.56 (95% CI: 0.30e1.03); when adjusting for history of
allergy, an OR of 0.71 (95% CI: 0.33e1.53; p ¼ 0.3835) was
found; therefore, the OR after adjustment for history of
allergy was closer to 1, suggesting a lesser effect of age on
the incidence of ADRs when taking into account a history
of allergy.
The incidence of nausea in the elderly (0.16%) versus
adults <65 years (0.2%) was not statistically different (OR:
0.81; 95% CI: 0.34e1.93; p ¼ 0.6317; Table 2). The rates of
occurrence of all other types of ADR were too low for
Table 1














Female 776 (45.73) 2094 (53.54) e
Male 921 (54.27) 1817 (46.46) e
Global region
Europe 1159 (68.30) 2093 (53.52) e














14 (0.82) 41 (1.05) 0.80 (0.39e1.48)
Nausea 12 (0.71) 26 (0.66) 1.09 (0.49e2.19)




17 (1.00) 28 (0.72) 1.42 (0.72e2.66)
Feeling hot 8 (0.47) 10 (0.26) 1.87 (0.63e5.21)
Injection site pain 2 (0.12) 8 (0.20) 0.68 (0.06e2.89)
Investigations 2 (0.12) 19 (0.49) 0.29 (0.03e1.00)
Nervous system
disorders
10 (0.59) 44 (1.13) 0.54 (0.23e1.05)
Dizziness 1 (0.06) 8 (0.20) 0.41 (NAe2.15)
Dysgeusia 3 (0.18) 17 (0.43) 0.46 (0.08e1.41)




7 (0.41) 21 (0.54) 0.80 (0.28e1.88)
Vascular disorders 0 5 (0.13) 0.21 (NAe2.52)b
ADR, adverse drug reaction; b.w., body weight; CI, conﬁdence interval; SOC,
system organ class.
a Those SOCs for which at least ﬁve reports per age group were reported.
b The value 0.5 was added to each cell of the 22 table to avoid zero counts
in any cell when estimating the odds ratio. Statistical comparison not made.
Table 2














Gender (n ¼ 13808)a
Female 2176 (50.41) 5206 (54.85) e
Male 2141 (49.59) 4285 (45.15) e
Administered dose
(mmol/kg b.w.)b
<0.10 628 (14.65) 1697 (17.97) e
0.10 < 0.20 2230 (52.01) 5224 (55.33) e
0.20 < 0.30 1091 (25.44) 2126 (22.52) e
0.30 339 (7.91) 394 (4.17) e
History of allergy
(any)c
Yes 344 (10.23) 897 (13.89) e
No 3018 (89.77) 5563 (86.12)
Total experiencing
any ADR




Agitation 0 1 (0.01) e
Anaphylactic reaction 1 (0.02) 0 e
Cephalgia 0 1 (0.01) e
Chills 0 1 (0.01) e
Circulatory collapse 0 1 (0.01) e
Cough 0 1 (0.01) e
Dyspnoea 1 (0.02) 1 (0.01) e
Erythema (facial) 1 (0.02) 0 e
Feeling of warmth 0 3 (0.03) e
Flushing 0 2 (0.02) e
Itching 0 1 (0.01) e
Itchy throat 0 2 (0.02) e




Malaise 0 1 (0.01) e
Mucosal swelling 0 1 (0.01) e
Nausea 7 (0.16) 19 (0.20) 0.81 (0.34e1.93);
p ¼ 0.6317
Nausea (aggravated) 1 (0.02) 0 e
Oral dryness 0 1 (0.01) e
Paraesthesia (hand) 0 1 (0.01) e
Pruritus 0 1 (0.01) e
Redness (facial) 0 0 e
Sensation of heat 0 1 (0.01) e
Skin disorder 0 2 (0.02) e
Skin reaction 0 1 (0.01) e
J. Endrikat et al. / Clinical Radiology 70 (2015) 743e751746statistical comparison, including serious ADR (one reported
in each age group).7Sore throat 0 1 (0.01) e
Stomach pain 1 (0.02) 0 e
Swelling 0 1 (0.01) e
Swelling of the lips 0 1 (0.01) e
Urticaria 0 2 (0.02) e
Vasodilation 0 2 (0.02) e
Vasovagal reaction 0 1 (0.01) e
Vomiting 1 (0.02) 0 e
Statistical comparison not made.
ADR, adverse drug reaction; b.w., body weight; CI, conﬁdence interval;
MedDRA, Medical Dictionary for Regulatory Activities.
a Data missing in 256 patients (173 aged 18e64 years and 83 in those 65
years).
b Data missing in 335 patients (223 aged 18e64 years and 112 in those
65 years).
c Data missing in 4242 patients (3204 aged 18e64 years and 1038 in those
65 years).Pharmacovigilance reporting data
The pharmacovigilance database included 2031 patients
for whom ADRs had been reported between 1999 and the
cut-off date of 26 February 2013; 1701 adults aged <65
years and 330 elderly (Table 3). The global regions from
which reports were received were similar between the
elderly and younger adult populations. A greater proportion
of reports were received regarding ADRs in female versus
male adults <65 years (64% and 34%, respectively; Table 3),
while the ratio of ADRs in male and female elderly patients
was equal (49% for each). Most pharmacovigilance reports
were spontaneous (>97% in both age groups), with a small
Table 3
Characteristics of the population for whom adverse drug reactions were





Total population (n ¼ 2031) 330 1701
Gender
Female 162 (49.09) 1091 (64.14)
Male 162 (49.09) 572 (33.63)
Missing data 6 (1.82) 38 (2.23)
Global region
Europe 224 (67.88) 1053 (61.90)
Rest of world 106 (32.12) 648 (38.10)
Origin of report
Spontaneous 323 (97.88) 1691 (99.41)
Study 4 (1.21) 8 (0.47)
Published report of study 2 (0.61) 0
Literature 1 (0.30) 2 (0.12)
J. Endrikat et al. / Clinical Radiology 70 (2015) 743e751 747number of entries from observational studies, study reports,
and published literature (Table 3).
The total number of ADRs (1999e2013) included in the
analysis was 1834; 1533 in patients aged 18e64 years and
301 in elderly patients (age data not available in 197 pa-
tients). The distribution of ADR reports over time was not
found to be signiﬁcantly different between the age groups.
A total of 600 patients reported 656 serious ADRs following
gadobutrol administration; 474 (79%) of these patients were
adults <65 years and 126 (21%) were elderly. Serious ADRs
per patient by SOC are shown in Fig 1. Some variances be-
tween the age groups with respect to incidences involving
each SOC were demonstrated; however, there was found to
be, overall, no signiﬁcant difference in the distribution of
type of serious ADRs between the age groups (p¼ 0.1497). A
record of death (at least possibly related to gadobutrol
administration) was included for 16 of 1663 (1.0%) adults
aged 18e64 years for whom an ADR was reported and data
were available, and for seven of 324 (2.2%) elderly patients.Figure 1 Serious adverse drug reactions (ADRs) per subject, by system o
patients, 1999e2013).Seven of the 16 deaths in adults aged<65 years and three of
the seven deaths in elderly patients were associated with an
acute anaphylactic reaction to contrast medium adminis-
tration, which is a known adverse event previously reported
in less than 0.5% of patients.9,10 The trend for a higher per-
centage of mortality in elderly patients (2.2% versus 1.0% for
adults) was not found to be signiﬁcant (OR: 2.27; 95% CI:
0.93e5.57; p ¼ 0.0831), but may be partially related to the
higher morbidity expected in the elderly population (four of
seven elderly patients suffered adverse events potentially
related to underlying conditions or an unknown cause).
Gender, region, and the respective interactions were not
found to inﬂuence the incidence of deaths between the age
groups signiﬁcantly.
Utilisation data for gadobutrol during the period 2007 to
2011 (based on volume sold and AMR data) suggested a
total of 13 million procedures were performed; 67.2% (8.74
million) in adults <65 years and 30.3% (3.94 million) in the
elderly (the remaining 2.5% of procedures were performed
in paediatric patients). The estimated distribution of body
regions for which these examinations were performed are
shown in Table 4. During this period, a total of 1145 ADRs
were reported following an estimated 12.67 million ad-
ministrations in patients aged 18 years; 958 (0.011%) in
those aged 18e64 years and 187 (0.005%) in patients 65
years (Table 4). It might be anticipated that the rate of ADRs
in each patient group would be proportional to the number
of gadobutrol-enhanced examinations performed; howev-
er, the 30.3% of procedures performed in elderly patients
accounted for only 16.3% of the 1145 ADRs reported, which
is proportionally around half that which could have been
expected (Fig 2; p < 0.0001). All ADRs reported during the
period 2007e2011 for each age group are shown in Table 4,
listed by SOC. There was a similar distribution of ADRs by
SOC between the age groups (p ¼ 0.5660). Serious ADRs
were reported in 334 (0.0038%) adults <65 years and 87
(0.0022%) elderly patients. The comparison of the in-
cidences of serious ADRs favouring elderly patients wasrgan class, in the pharmacovigilance population (656 events in 600
Table 4
Utilisation data on gadobutrol-enhanced MRI procedures between 2007 and
2011,a by body region,b and incidence of adverse drug reactions during this






(n [ 12.67 million)c
3.94 million (30.3) 8.74 million (67.2)
Body regionb
Central nervous system 1.52 million (38.7) 3.63 million (41.6)
Blood vessels (angiography) 1.47 million (37.3) 2.01 million (23.0)
Extremities 0.19 million (4.7) 1.01 million (11.6)
Abdomen 0.13 million (3.3) 0.40 million (4.5)
Liver 0.12 million (3.2) 0.29 million (3.4)
Head/face/neck 0.12 million (3.1) 0.32 million (3.6)
Pelvis 0.12 million (3.0) 0.34 million (3.9)
Breast 0.07 million (1.7) 0.35 million (4.1)
Chest 0.04 million (1.1) 0.14 million (1.6)
Prostate 0.06 million (1.6) 0.04 million (0.5)
Kidney 0.06 million (1.4) 0.10 million (1.1)
Heart 0.02 million (0.5) 0.05 million (0.5)
Other 0.02 million (0.5) 0.05 million (0.5)
Total ADRs 187 (0.005) 958 (0.011)
ADRs by SOC preferred
term relative to the
utilisation data
Blood and lymphatic system
disorder
1 (<0.0001) 0
Cardiac disorder 7 (0.0002) 23 (0.0003)
Ear and labyrinth disorder 0 6 (0.0001)
Eye disorder 4 (0.0001) 29 (0.0003)




14 (0.0004) 65 (0.0007)
Hepatobiliary disorder 0 1 (<0.0001)
Immune system disorder 17 (0.0004) 104 (0.0012)
Infections and infestations 3 (0.0001) 8 (0.0001)
Injury, poisoning,
procedural, complication
1 (<0.0001) 9 (0.0001)
Investigations 2 (0.0001) 7 (0.0001)
Musculoskeletal/connective
tissue disorder
2 (0.0001) 6 (0.0001)




Psychiatric disorders 1 (<0.0001) 2 (<0.0001)
Renal and urinary disorders 2 (0.0001) 2 (<0.0001)
Respiratory, thoracic and
mediastinal disorders
20 (0.0005) 112 (0.0013)
Skin and subcutaneous
tissue disorders
53 (0.0013) 296 (0.0034)
Vascular disorders 3 (0.0001) 22 (0.0003)
Serious ADRs 87 (0.0022) 334 (0.0038)
Deaths 4 (0.0001) 13 (0.0001)
ADR, adverse drug reaction; SOC, system organ class.
a Using litre volume sold according to Bayer internal sales reporting.
b Percentage distribution according to Arlington Medical Resources (AMR)
for Gadovist during 2007e2011. AMR covers Europe, USA, and Asia. Per-
centage distribution was provided rounded to one decimal place for each
body region and absolute numbers are estimated from these data.
c Adults 18 years of age; a further 0.33 million administrations occurred
in paediatric patients.
Figure 2 Proportions of contrast-enhanced procedures performed
and adverse drug reactions (ADRs) reported during the period
2007e2011, based on utilisation data. (a) Percentage of an estimated
12.67 million procedures, using utilisation data from litre volume sold
according to Bayer internal sales. (b) Percentage of 1145 reported
ADRs.
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p < 0.0001). Deaths at least possibly related to gadobutrol
administration occurred in 13 of 1006 (1.3%) adults aged
<65 years for whom an ADR was reported and data wereavailable, and 4 of 192 (2.1%) elderly patients. The difference
in incidence of death in favour of the adults aged <65 years
was found not to be signiﬁcant (OR: 1.63; 95% CI:
0.52e5.04; p ¼ 0.3346). An estimated death rate, based on
utilisation data for 2007e2011, would be 1.49 per million
doses (13 in 8.74 million, 0.0001%) in adults <65 years and
1.02 per million doses (four in 3.94 million, 0.0001%) in
elderly patients. These estimated death rates are within the
range previously reported for GBCA use in the USA
(0.15e2.7 deaths per million doses).11
Summary
Our data suggest that rates of reported ADRs were lower
in elderly patients aged 65 years compared with adults
aged <65 years, with statistical signiﬁcance demonstrated
for the clinical trials and pharmacovigilance populations
and a trend for a lower incidence in elderly patients in the
PMS database (Fig 3).
Discussion
This analysis of the safety of gadobutrol in adults aged
<65 years and in the elderly (65 years) included a large
number of subjects and demonstrated a low rate of ADRs in
both age groups, with similar results from each of the three
data sources analysed. These data conﬁrm the favourable
safety proﬁle of gadobutrol, as reported from a number of
previous studies.1e3,7 However, to the authors’ knowledge,
this is the ﬁrst large study to speciﬁcally investigate the
Figure 3 Comparison of overall ADR rates for elderly versus adult patients from each database analysed. (a) Pharmacovigilance ADR rate based
upon utilisation data for the number of administrations during the period 2007e2011, using litre volume sold according to Bayer internal sales
reporting.
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lower incidence of non-serious ADRs was demonstrated in
these patients versus adults aged <65 years.
The well-being of elderly people is of growing concern,
due to an increase in the proportion of this age group
worldwide, especially in Asian countries such as Japan
(where the percentage of elderly people has quadrupled in
50 years, from 5.7% to 23.1%).12 It is important to assess the
safety of drugs in elderly patients, as this population can
demonstrate greater comorbidity and frailty than younger
adults.5 Renal function may also be lower in elderly pa-
tients, which may have an inﬂuence on the elimination rate
of drugs and contrast media. The lower rate of reported
ADRs demonstrated for elderly patients who received
gadobutrol may appear counterintuitive, given the greater
likelihood of comorbidity in this population. An explanation
for this ﬁnding may be that elderly patients have a less
active immune system due to aging-related immunose-
nescence and immune remodelling,13 andmay be less likely
to have an overt reaction to an allergic stimulus. Alterna-
tively, it has been suggested that the elderly may be less
likely to report ADRs (as they are for symptoms of illness in
general) due to considering these a “normal” part of aging,
as well as concerns over being dismissed or needing
burdensome tests, or communication problems, including
hearing and speech deﬁcits.14
Each of the three databases analysed (clinical trials,
PMS, and pharmacovigilance) yielded a similar result with
regard to a lower rate of reported non-serious ADRs in
elderly versus adults <65 years. This inter-database
conﬁrmation fosters conﬁdence in the conclusion that
gadobutrol demonstrates a favourable safety proﬁle in
elderly patients. It is notable that the overall rate of ADRreporting was higher in the clinical trials database
compared with the other two spontaneous-reporting
sources. Under-reporting of ADRs in post-marketing clin-
ical use has been widely reported in the literature,15e17 and
this phenomenon may partially explain the difference in
ADR incidence between the data sources.
A greater proportion of higher dosing of gadobutrol
was noted for elderly versus adults aged <65 years in the
PMS database; this may be related to a greater proportion
of magnetic resonance angiography (MRA) procedures in
these patients (as noted in the utilisation data, Table 4;
37.3% elderly versus 23.0% adults <65 years), for which
higher dosing is indicated (standard dosing of gadobutrol
for MRI of all body regions is 0.1 mmol/kg b.w., while
standard dosing for MRA is 0.1e0.15 mmol/kg b.w. for one
ﬁeld of view and 0.2e0.3 mmol/kg b.w. for more than one
ﬁeld of view). As utilisation data for gadobutrol use were
based on an average dose of 10 ml per MRI examination,
a higher average dose of gadobutrol in elderly patients
may have led to an overestimation of the number of
examinations performed in these patients. This may, in
part, account for the lower than expected ADR rate in
elderly subjects within the pharmacovigilance database;
however, if this assumption is made, it would follow that
no increase in ADR incidence was associated with a
higher dose. The PMS data also suggested an association
between ADR incidence and patient history of allergy.
These data support previous ﬁndings for GBCA, suggest-
ing that the frequency of ADRs in patients with previous
allergies is almost double that in subjects with no known
allergies.18
In the pharmacovigilance database, a greater proportion
of ADRs were reported in female versus male adults aged
J. Endrikat et al. / Clinical Radiology 70 (2015) 743e751750<65 years, while for elderly patients the incidence of ADRs
was similar between the genders. Female gender is a known
risk factor for ADRs generally, due to differences in phar-
macokinetics and pharmacodynamics between the sexes;
speciﬁcally, females have a higher percentage of body fat
(which can affect the volume of drug distribution), reduced
renal clearance, and altered hormone and enzyme activities
compared with males.19 Females have also been noted to
experience a higher incidence of drug-induced liver toxicity
and allergic skin rashes versus males.19 The equivalent rate
of ADRs in both genders of elderly patients in this database
may be partially explained by potentially smaller differ-
ences in hormone levels, renal function, and body compo-
sition between females and males with advancing age.20,21
Other studies involving a number of different pharmaco-
logical agents have reported that female gender as a risk
factor for ADRs persists for elderly patients,22,23 while an
American prospective cohort study found no inﬂuence of
age or gender on ADR rates in multivariate analyses of
ambulatory patients.24 Therefore, further research may be
required to fully elucidate the role of female gender on
susceptibility for ADRs generally, and speciﬁcally, with re-
gard to contrast media reactions rather than those to
pharmacological agents.
Although the present study demonstrated strength in
the consistent outcomes gained from a large number of
patients in three separate data sources, it also had some
limitations. The overall incidence of serious adverse re-
actions to contrast media is very low; therefore, the
numbers of serious ADRs in the clinical trials and PMS
populations were too low to allow statistical comparison
between the age groups. Additionally, spontaneous
reporting of ADRs following gadobutrol administration may
have resulted in under-reporting of mild and moderate
ADRs.
Reports of total ADRs following gadobutrol administra-
tion have been increasing in proportion with the growth in
worldwide availability and the numbers of procedures
performed; however, the future incidence of ADRs is pre-
dicted to remain stable or to decline below the current low
rates due to a wider understanding of ADR risk factors and
preventative measures, and a trend for reduced contrast
media dosing.25e27
In conclusion, this comprehensive evaluation of data
conﬁrms the favourable safety proﬁle of gadobutrol in
general, and in particular, in elderly patients (65 years).
The study utilised three separate data sources (clinical
trials, PMS, and pharmacovigilance data) and demon-
strated that non-serious ADRs were consistently less
frequent in elderly patients compared with younger adults.
A lower incidence of history of allergies may, in part,
explain the reduced ADR rates in elderly compared with
younger adult patients, and the likelihood of spontaneous
reporting of mild ADRs may be lower in the elderly pop-
ulation. These data suggest that there is no greater inci-
dence of ADRs following gadobutrol-enhanced MRI in
elderly patients compared with younger adults, and that
gadobutrol has a favourable safety proﬁle in both age
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